AcelRx announces FDA approval of DSUVIAâ„¢

Author's Avatar
Nov 02, 2018
Article's Main Image

- DSUVIA (sufentanil sublingual tablet 30 mcg) is indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings

- First and only sufentanil sublingual tablet approved for acute pain in healthcare settings

- DSUVIA U.S. launch expected in the first quarter of 2019

- Conference-call scheduled for Monday, November 5th at 8:30 a.m. ET

PR Newswire